Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.
March 2024 in “Cancer Research” Eliminating senescent cells can prevent and reverse chemotherapy-induced peripheral neuropathy.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Sonidegib effectively treated basal cell carcinoma in a patient with lupus without worsening lupus symptoms.
15 citations
,
July 2023 in “EClinicalMedicine” ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.
January 2024 in “Skin Appendage Disorders” Eyelash loss can temporarily occur from chemotherapy for retinoblastoma.
522 citations
,
January 2001 in “Cancer investigation” Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.
9 citations
,
February 2012 in “Cancer Chemotherapy and Pharmacology” The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.
4 citations
,
August 2016 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Using cetirizine on the skin and taking vitamin D can help increase hair growth in children with hair loss from ectodermal dysplasia.
9 citations
,
May 2019 in “Experimental Cell Research” HPV genes and estradiol increase a cancer-related signaling pathway, which may be targeted for cervical cancer treatment.
March 2009 in “European Urology Supplements”
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
26 citations
,
June 2003 in “PubMed” Alpha-difluoromethylornithine prevents cancer in mice but causes hair loss.
1 citations
,
July 2014 in “International Journal of Dermatology” A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.
26 citations
,
February 2015 in “Pediatric blood & cancer” Targeted anticancer therapies in children often cause skin side effects like rash and dry skin.
2 citations
,
January 2014 in “Journal of Cytology & Histology” Rapamycin and anti-EGFR antibody reduce LAM/TSC cell migration and blood vessel growth in the uterus.
October 2023 in “Naunyn-Schmiedeberg's Archives of Pharmacology” Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
1 citations
,
February 2018 in “Orthopedics and rheumatology” Combining Western chemotherapy with Traditional Chinese Medicine can reduce side effects and improve immune response in treating bone and soft tissue tumors.
August 2023 in “Frontiers in Oncology” New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
14 citations
,
October 2003 in “Annals of Oncology” About half the patients treated with capecitabine and docetaxel developed severe hand-foot syndrome.
2 citations
,
April 2010 in “Cancer Research” Removing EGFR in skin causes inflammation and abnormal hair growth.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Applying the anti-cancer drug Bortezomib to skin can promote hair growth and increase hair proteins through the GATA-3 factor.
32 citations
,
May 2016 in “European journal of dermatology/EJD. European journal of dermatology” Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.
57 citations
,
August 2006 in “Journal of the American Academy of Dermatology” Gefitinib can cause hair loss without scarring.
17 citations
,
July 2024 in “Frontiers in Oncology” New therapies and trials are needed for Merkel cell carcinoma, a tough skin cancer.
1 citations
,
January 2022 in “Journal of Cancer Therapy” Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.
1 citations
,
July 2025 in “Clinical and Experimental Dermatology” Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
35 citations
,
January 2004 in “European journal of oncology nursing” Capecitabine is as effective as intravenous treatments with fewer side effects, but requires careful management of Hand-foot syndrome and patient education.
5 citations
,
May 2008 in “Annals of saudi medicine/Annals of Saudi medicine” Cabergoline helped a boy with Cushing disease get better after surgery and radiotherapy didn't work.